Skip to main navigation Skip to main content

CMH : Clinical and Molecular Hepatology

OPEN ACCESS
ABOUT
BROWSE ARTICLES
FOR CONTRIBUTORS

Page Path

1
results for

"Tae Won Kim"

Article category

Keywords

Publication year

"Tae Won Kim"

Original Article

Hepatic neoplasm

Fibroblast growth factor receptor isotype expression and its association with overall survival in patients with hepatocellular carcinoma
Hyo Jeong Lee, Hyo Jeong Kang, Kang Mo Kim, Eun Sil Yu, Ki Hun Kim, Seung-Mi Kim, Tae Won Kim, Ju Hyun Shim, Young-Suk Lim, Han Chu Lee, Young-Hwa Chung, Yung Sang Lee
Clin Mol Hepatol 2015;21(1):60-70.
Published online March 25, 2015
DOI: https://doi.org/10.3350/cmh.2015.21.1.60
Background/Aims

Fibroblast growth factor signaling is involved in hepatocarcinogenesis. The aim of this study was to determine the fibroblast growth factor receptor (FGFR) isotype expression in hepatocellular carcinoma (HCC) and neighboring nonneoplastic liver tissue, and elucidate its prognostic implications.

Methods

Immunohistochemical staining of FGFR1, -2, -3, and -4 was performed in the HCCs and paired neighboring nonneoplastic liver tissue of 870 HCC patients who underwent hepatic resection. Of these, clinical data for 153 patients who underwent curative resection as a primary therapy were reviewed, and the relationship between FGFR isotype expression and overall survival was evaluated (development set). This association was also validated in 73 independent samples (validation set) by Western blot analysis.

Results

FGFR1, -2, -3, and -4 were expressed in 5.3%, 11.1%, 3.8%, and 52.7% of HCCs, respectively. Among the development set of 153 patients, FGFR2 positivity in HCC was associated with a significantly shorter overall survival (5-year survival rate, 35.3% vs. 61.8%; P=0.02). FGFR2 expression in HCC was an independent predictor of a poor postsurgical prognosis (hazard ratio, 2.10; P=0.02) in the development set. However, the corresponding findings were not statistically significant in the validation set.

Conclusions

FGFR2 expression in HCC could be a prognostic indicator of postsurgical survival.

Citations

Citations to this article as recorded by  Crossref logo
  • Activated FGFR2 signalling as a biomarker for selection of intrahepatic cholangiocarcinoma patients candidate to FGFR targeted therapies
    Giovanni Brandi, Valeria Relli, Marzia Deserti, Andrea Palloni, Valentina Indio, Annalisa Astolfi, Salvatore Serravalle, Alessandro Mattiaccio, Francesco Vasuri, Deborah Malvi, Chiara Deiana, Maria Abbondanza Pantaleo, Matteo Cescon, Alessandro Rizzo, Mas
    Scientific Reports.2024;[Epub]     CrossRef
  • Evolving therapeutic landscape of advanced hepatocellular carcinoma
    Chen Yang, Hailin Zhang, Linmeng Zhang, Andrew X. Zhu, René Bernards, Wenxin Qin, Cun Wang
    Nature Reviews Gastroenterology & Hepatology.2023; 20(4): 203.     CrossRef
  • Dietary Fat Composition Affects Hepatic Angiogenesis and Lymphangiogenesis in Hepatitis C Virus Core Gene Transgenic Mice
    Pan Diao, Yaping Wang, Fangping Jia, Xiaojing Wang, Xiao Hu, Takefumi Kimura, Yoshiko Sato, Kyoji Moriya, Kazuhiko Koike, Jun Nakayama, Naoki Tanaka
    Liver Cancer.2023; 12(1): 57.     CrossRef
  • Genomic Relevance of FGFR2 on the Prognosis of HCV-Induced Hepatocellular Carcinoma Patients
    Walizeb Khan, Washaakh Ahmad, Anwar M. Hashem, Shadi Zakai, Shafiul Haque, Muhammad Faraz Arshad Malik, Steve Harakeh, Farhan Haq
    Journal of Clinical Medicine.2022; 11(11): 3093.     CrossRef
  • Prognostic Role of Molecular and Imaging Biomarkers for Predicting Advanced Hepatocellular Carcinoma Treatment Efficacy
    Lucia Cerrito, Maria Elena Ainora, Carolina Mosoni, Raffaele Borriello, Antonio Gasbarrini, Maria Assunta Zocco
    Cancers.2022; 14(19): 4647.     CrossRef
  • AZD4547 and the Alleviation of Hepatoma Cell Sorafenib Resistance via the Promotion of Autophagy
    Yun Feng, Dan Zhang, Gaixia He, Yaping Liu, Yan Zhao, Xiaoyang Ren, Huanhuan Sun, Guifang Lu, Zhiyong Zhang, Li Ren, Yan Yin, Hongxia Li, Shuixiang He
    Anti-Cancer Agents in Medicinal Chemistry.2022; 22(18): 3107.     CrossRef
  • Combination of molecularly targeted therapies and immune checkpoint inhibitors in the new era of unresectable hepatocellular carcinoma treatment
    Ze-Long Liu, Jing-Hua Liu, Daniel Staiculescu, Jiang Chen
    Therapeutic Advances in Medical Oncology.2021;[Epub]     CrossRef
  • Fibroblast growth factor signaling in non-alcoholic fatty liver disease and non-alcoholic steatohepatitis: Paving the way to hepatocellular carcinoma
    Matthias Ocker
    World Journal of Gastroenterology.2020; 26(3): 279.     CrossRef
  • Tumor-Stroma Crosstalk Enhances REG3A Expressions that Drive the Progression of Hepatocellular Carcinoma
    Yuri Cho, Min Ji Park, Koeun Kim, Jae-Young Park, Jihye Kim, Wonjin Kim, Jung-Hwan Yoon
    International Journal of Molecular Sciences.2020; 21(2): 472.     CrossRef
  • Early Changes in Circulating FGF19 and Ang-2 Levels as Possible Predictive Biomarkers of Clinical Response to Lenvatinib Therapy in Hepatocellular Carcinoma
    Makoto Chuma, Haruki Uojima, Kazushi Numata, Hisashi Hidaka, Hidenori Toyoda, Atsushi Hiraoka, Toshifumi Tada, Shunji Hirose, Masanori Atsukawa, Norio Itokawa, Taeang Arai, Makoto Kako, Takahide Nakazawa, Naohisa Wada, Shuitirou Iwasaki, Yuki Miura, Satos
    Cancers.2020; 12(2): 293.     CrossRef
  • First-in-Human Phase I Study of Aprutumab Ixadotin, a Fibroblast Growth Factor Receptor 2 Antibody–Drug Conjugate (BAY 1187982) in Patients with Advanced Cancer
    Sung-Bae Kim, Funda Meric-Bernstam, Aparna Kalyan, Aleksei Babich, Rong Liu, Takahiko Tanigawa, Anette Sommer, Motonobu Osada, Frank Reetz, Dirk Laurent, Sabine Wittemer-Rump, Jordan Berlin
    Targeted Oncology.2019; 14(5): 591.     CrossRef
  • The Current Landscape of Systemic Therapies for Advanced Hepatocellular Carcinoma
    Prachi Rana, John Haydek, Anjana Pillai
    Current Hepatology Reports.2019; 18(4): 371.     CrossRef
  • Tumor‐adjacent tissue co‐expression profile analysis reveals pro‐oncogenic ribosomal gene signature for prognosis of resectable hepatocellular carcinoma
    Oleg V. Grinchuk, Surya P. Yenamandra, Ramakrishnan Iyer, Malay Singh, Hwee Kuan Lee, Kiat Hon Lim, Pierce Kah‐Hoe Chow, Vladamir A. Kuznetsov
    Molecular Oncology.2018; 12(1): 89.     CrossRef
  • Molecular therapies and precision medicine for hepatocellular carcinoma
    Josep M. Llovet, Robert Montal, Daniela Sia, Richard S. Finn
    Nature Reviews Clinical Oncology.2018; 15(10): 599.     CrossRef
  • Higher serum interleukin-17A levels as a potential biomarker for predicting early disease progression in patients with hepatitis B virus-associated advanced hepatocellular carcinoma treated with sorafenib
    Hyo Jung Cho, Soon Sun Kim, Ji Sun Nam, Min Jung Oh, Dae Ryong Kang, Jai Keun Kim, Jei Hee Lee, Bohyun Kim, Min Jae Yang, Jae Chul Hwang, Sun Gyo Lim, Sung Jae Shin, Kee Myung Lee, Byung Moo Yoo, Kwang Jae Lee, Sung Won Cho, Jae Youn Cheong
    Cytokine.2017; 95: 118.     CrossRef
  • Prognostic role of fibroblast growth factor receptor 2 in human solid tumors: A systematic review and meta-analysis
    Gang Liu, Disheng Xiong, Rui Xiao, Zhengjie Huang
    Tumor Biology.2017; 39(6): 101042831770742.     CrossRef
  • Hypoxia Enhances Tumor-Stroma Crosstalk that Drives the Progression of Hepatocellular Carcinoma
    Yuri Cho, Eun Ju Cho, Jeong-Hoon Lee, Su Jong Yu, Yoon Jun Kim, Chung Yong Kim, Jung-Hwan Yoon
    Digestive Diseases and Sciences.2016; 61(9): 2568.     CrossRef
  • 125I-labeled anti-bFGF monoclonal antibody inhibits growth of hepatocellular carcinoma
    Peng-Hui Hu, Lan-Hong Pan, Patrick Ting-Yat Wong, Wen-Hui Chen, Yan-Qing Yang, Hong Wang, Jun-Jian Xiang, Meng Xu
    World Journal of Gastroenterology.2016; 22(21): 5033.     CrossRef
  • Prognostic roles for fibroblast growth factor receptor family members in malignant peripheral nerve sheath tumor
    Wenya Zhou, Xiaoling Du, Fengju Song, Hong Zheng, Kexin Chen, Wei Zhang, Jilong Yang
    Oncotarget.2016; 7(16): 22234.     CrossRef
  • MicroRNA-126 inhibits tumor proliferation and angiogenesis of hepatocellular carcinoma by down-regulating EGFL7 expression
    Ming-Hua Hu, Chen-Yang Ma, Xiao-Ming Wang, Chen-Dong Ye, Guang-Xian Zhang, Lin Chen, Jin-Guo Wang
    Oncotarget.2016; 7(41): 66922.     CrossRef
  • NGS-based identification of druggable alterations and signaling pathways – hepatocellular carcinoma case report
    E. A. Kotelnikova, M. D. Logacheva, E. R. Nabieva, M. A. Pyatnitskiy, D. V. Vinogradov, A. S. Makarova, A. V. Demin, A. G. Paleeva, O. S. Kremenetskaya, A. A. Penin, A. V. Klepikova, A. S. Kasianov, D. A. Shavochkina, N. E. Kudashkin, Yu. I. Patyutko, N.
    Biopolymers and Cell.2015; 31(6): 436.     CrossRef
  • 11,453 View
  • 135 Download
  • 21 Web of Science
  • Crossref